Last reviewed · How we verify
d-cycloserine
D-cycloserine is a partial agonist at the N-methyl-D-aspartate (NMDA) receptor glycine site, enhancing glutamatergic neurotransmission in the central nervous system.
D-cycloserine is a partial agonist at the N-methyl-D-aspartate (NMDA) receptor glycine site, enhancing glutamatergic neurotransmission in the central nervous system. Used for Tuberculosis (as an adjunctive agent), Obsessive-compulsive disorder (adjunctive to cognitive-behavioral therapy), Post-traumatic stress disorder (adjunctive to cognitive-behavioral therapy).
At a glance
| Generic name | d-cycloserine |
|---|---|
| Also known as | Experimental Group, Cycloserine, Seromycin, Cycloserine, King Pharmaceuticals Ltd, D-cycloserine, Cycloserine, DCS |
| Sponsor | Massachusetts General Hospital |
| Drug class | NMDA receptor partial agonist |
| Target | NMDA receptor (glycine site) |
| Modality | Small molecule |
| Therapeutic area | Psychiatry/Neurology |
| Phase | FDA-approved |
Mechanism of action
D-cycloserine binds to the glycine modulatory site on NMDA receptors, potentiating their function by facilitating the opening of the ion channel. This enhancement of NMDA receptor activity is thought to facilitate learning and memory consolidation, making it useful as an adjunctive agent in cognitive-behavioral therapy for anxiety and trauma-related disorders.
Approved indications
- Tuberculosis (as an adjunctive agent)
- Obsessive-compulsive disorder (adjunctive to cognitive-behavioral therapy)
- Post-traumatic stress disorder (adjunctive to cognitive-behavioral therapy)
Common side effects
- Peripheral neuropathy
- Headache
- Dizziness
- Psychosis or psychiatric symptoms
- Seizures
Key clinical trials
- A Pilot Trial of One-Day Accelerated TMS and D-cycloserine in Suicidal Patients With Borderline Personality Disorder (PHASE1, PHASE2)
- AIH for Spinal Cord Repair (EARLY_PHASE1)
- Assisting Smokers to Switch to an e-Cigarette by Accelerating Learning of Adaptive Habits Using D-cycloserine (PHASE2)
- D-Cycloserine Augmentation of Intermittent Theta Burst Stimulation (iTBS) in Depression (COGENT) (PHASE2)
- A Randomized, Double-Blind Controlled Comparison of NRX-101 vs. Placebo for Adults Being Treated With Transcranial Magnetic Stimulation for Treatment Resistant Depression (PHASE2, PHASE3)
- 6 Months of Bedaquiline(BDQ), Delamanid(DLM), Linezolid(LZD) and Levofloxacin(LFX) in RR-TB Patients in Hubei Province (NA)
- iTBS-DCS in Fibromyalgia (PHASE2)
- iTBS+D-Cycloserine for Youth Suicide (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- d-cycloserine CI brief — competitive landscape report
- d-cycloserine updates RSS · CI watch RSS
- Massachusetts General Hospital portfolio CI